Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses

Reuters

11/04

Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss wider than expected on higher R&D expenses

Overview

Beam Therapeutics Q3 net loss misses analyst expectations
Company ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028
Beam progressing with BEAM-302 and BEAM-101 clinical trials

Outlook

Beam expects to report BEAM-302 trial data in early 2026
Company plans to present BEACON trial data at ASH meeting in December 2025
Beam's cash runway expected to support operations into 2028

Result Drivers

CASH POSITION - Beam ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028
R&D EXPENSES - Increased R&D expenses to $109.8 mln in Q3 2025, contributing to net loss

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 License and Collaboration Revenue		$9.69 mln
Q3 Net Income	Miss	-$112.72 mln	-$96.50 mln (11 Analysts)
Q3 Operating Income	Miss	-$126.81 mln	-$107 mln (11 Analysts)
Q3 Pretax Profit	Miss	-$112.72 mln	-$105.50 mln (9 Analysts)
Q3 Operating Expenses		$136.50 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Beam Therapeutics Inc is $42.50, about 42.9% above its November 3 closing price of $24.25

Press Release: ID:nGNXbt2k6Y

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580736107"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580736107\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580736107?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580736107","market":"fut","top_or_hot":-1,"title":"Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss wider than expected on higher R&amp;D expenses</title></head><body><p><span>Overview</span></p><ul><li><p>Beam Therapeutics Q3 net loss misses analyst expectations</p></li><li><p>Company ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028</p></li><li><p>Beam progressing with BEAM-302 and BEAM-101 clinical trials</p></li></ul><p><span>Outlook</span></p><ul><li><p>Beam expects to report BEAM-302 trial data in early 2026</p></li><li><p>Company plans to present BEACON trial data at ASH meeting in December 2025</p></li><li><p>Beam's cash runway expected to support operations into 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CASH POSITION - Beam ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028</p></li><li><p>R&amp;D EXPENSES - Increased R&amp;D expenses to $109.8 mln in Q3 2025, contributing to net loss</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 License and Collaboration Revenue</p></td><td></td><td><p>$9.69 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$112.72 mln</p></td><td><p>-$96.50 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Miss</p></td><td><p>-$126.81 mln</p></td><td><p>-$107 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Miss</p></td><td><p>-$112.72 mln</p></td><td><p>-$105.50 mln (9 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$136.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Beam Therapeutics Inc is $42.50, about 42.9% above its November 3 closing price of $24.25</p></li></ul><p>Press Release: <span>ID:nGNXbt2k6Y</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Q3 net loss wider than expected on higher R&D expenses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-04 20:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss wider than expected on higher R&amp;D expenses</title></head><body><p><span>Overview</span></p><ul><li><p>Beam Therapeutics Q3 net loss misses analyst expectations</p></li><li><p>Company ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028</p></li><li><p>Beam progressing with BEAM-302 and BEAM-101 clinical trials</p></li></ul><p><span>Outlook</span></p><ul><li><p>Beam expects to report BEAM-302 trial data in early 2026</p></li><li><p>Company plans to present BEACON trial data at ASH meeting in December 2025</p></li><li><p>Beam's cash runway expected to support operations into 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CASH POSITION - Beam ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028</p></li><li><p>R&amp;D EXPENSES - Increased R&amp;D expenses to $109.8 mln in Q3 2025, contributing to net loss</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 License and Collaboration Revenue</p></td><td></td><td><p>$9.69 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$112.72 mln</p></td><td><p>-$96.50 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Miss</p></td><td><p>-$126.81 mln</p></td><td><p>-$107 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Miss</p></td><td><p>-$112.72 mln</p></td><td><p>-$105.50 mln (9 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$136.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Beam Therapeutics Inc is $42.50, about 42.9% above its November 3 closing price of $24.25</p></li></ul><p>Press Release: <span>ID:nGNXbt2k6Y</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG0IT:1","article_id":"2580736107","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580736107","pubTimestamp":1762259039,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Beam Therapeutics Q3 net loss wider than expected on higher R&D expensesOverviewBeam Therapeutics Q3 net loss misses analyst expectationsCompany ended Q3 2025 with $1.1 bln in cash, supporting operati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BEAM":"Beam Therapeutics, Inc.","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4535":"淡马锡持仓","BK4611":"AI医疗"},"translate_title":"由于研发费用增加，Beam Therapeutics第三季度净亏损超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":0.9},"content_text":"Beam Therapeutics Q3 net loss wider than expected on higher R&D expensesOverviewBeam Therapeutics Q3 net loss misses analyst expectationsCompany ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028Beam progressing with BEAM-302 and BEAM-101 clinical trialsOutlookBeam expects to report BEAM-302 trial data in early 2026Company plans to present BEACON trial data at ASH meeting in December 2025Beam's cash runway expected to support operations into 2028Result DriversCASH POSITION - Beam ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028R&D EXPENSES - Increased R&D expenses to $109.8 mln in Q3 2025, contributing to net lossKey DetailsMetricBeat/MissActualConsensus EstimateQ3 License and Collaboration Revenue$9.69 mlnQ3 Net IncomeMiss-$112.72 mln-$96.50 mln (11 Analysts)Q3 Operating IncomeMiss-$126.81 mln-$107 mln (11 Analysts)Q3 Pretax ProfitMiss-$112.72 mln-$105.50 mln (9 Analysts)Q3 Operating Expenses$136.50 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Beam Therapeutics Inc is $42.50, about 42.9% above its November 3 closing price of $24.25Press Release: ID:nGNXbt2k6YFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}